A5102881029- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Immune cells in cancer
- CAR-T cell therapy research
- Radiopharmaceutical Chemistry and Applications
- Biochemical Analysis and Sensing Techniques
- Medical Imaging and Pathology Studies
- Radiomics and Machine Learning in Medical Imaging
- Women's cancer prevention and management
- Lung Cancer Treatments and Mutations
- Cancer, Hypoxia, and Metabolism
- Obesity, Physical Activity, Diet
- Melanoma and MAPK Pathways
- Diet and metabolism studies
- Global Cancer Incidence and Screening
Hospital Universitario Doctor Peset
2024
Clinica Universidad de Navarra
2021-2023
Universidad de Navarra
2020
Universidad de Granada
2014
Hospital Lluis Alcanyis
2012-2013
The use of PD-1/PD-L1 checkpoint inhibitors in advanced NSCLC is associated with longer survival. However, many patients do not benefit from blockade, largely because immunosuppression. New immunotherapy-based combinations are under investigation an attempt to improve outcomes. Id1 (inhibitor differentiation 1) involved In this study, we explored the potential synergistic effect combination inhibition and pharmacological PD-L1 blockade three different syngeneic murine KRAS-mutant lung...
The emergence of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis patients with solid tumors. However, along their efficacy, new toxicities related to system activation have surfaced, some which pose life-threatening risks. Cytokine release syndrome (CRS) and effector cell-associated neurotoxicity (ICANS) are among serious, albeit rare, immune-related adverse effects (irAEs) observed. Although commonly associated hematologic malignancies chimeric antigen receptor...
e12020 Background: Combining bevacizumab (BEV) with chemotherapy (CT) improves survival in HER2-negative metastatic breast cancer (MBC). We investigated the influence of age, ECOG, hormonal status, number sites, location metastases and patient decision on selection BEV combined CT MBC. Methods: Observational cross-sectional multicenter study patients HER2- negative MBC who have received first-line BEV. Results: 219 were included: median age 51(44-63) yr; ECOG: 0=53%; 60.4% pre-menopausic;...
e15116 Background: Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer treatment improving survival outcomes of non-small cell (NSCLC) patients. Response assessment patients on ICIs represents a challenge since an increase in tumor size or the appearance new lesions might not reflect true disease progression (P) but pseudoprogression (PP), which has been reported range 3-6% NSCLC. Conventional 18 F-FDG-PET scans do accurately discriminate P from PP. We recently efficacy...
e11074 Background: Combining bevacizumab (BEV) with chemotherapy (CT) improves survival in HER2-negative metastatic breast cancer (MBC). We investigated the influence of age, ECOG, hormonal status, number sites and location metastases patient decision on selection BEV combined CT MBC. Methods: Observational cross-sectional multicenter study pts MBC who have received first-line BEV. Results: From November 2010 to 2011, 124 were included: median age 51 (45-64) yr; ECOG: 0=50%; 60%...